Cold Spring Harbor Laboratory
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 9 name spellings.
5
Ending by 2030
Jan 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Structurally designed shRNAs (US 10,329,562) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Jan 9, 2027The maintenance fee for Compositions and Methods for Modulation of Ikbkap Splicing (US 10,344,282) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Genetic copy number determination using high throughput multiplex sequencing of smashed nucleotides (US 11,739,315) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Reducing nonsense-mediated mRNA decay (US 10,647,983) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,554,488 | Determining a Probabilistic Diagnosis of Autism by Analysis of Genomic Copy Number Variations In force · High confidence | In force | High confidence | |
| US 8,901,288 | High throughput methods for functionally determining RNA interference efficiency In force · From the USPTO record | In force | From the USPTO record | |
| US 8,895,526 | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers In force · From the USPTO record | In force | From the USPTO record | |
| US 8,980,853 | Compositions and Methods for Modulation of SMN2 Splicing in a Subject In force · High confidence | In force | High confidence | |
| US 8,361,977 | Compositions and Methods for Modulation of SMN2 Splicing In force · High confidence | In force | High confidence | |
| US 8,273,871 | Structurally designed shRNAs In force · From the USPTO record | In force | From the USPTO record | |
| US 8,993,532 | NOVEL STRUCTURALLY DESIGNED shRNAs In force · Medium confidence | In force | Medium confidence | |
| US 9,624,494 | Structurally designed shRNAs In force · From the USPTO record | In force | From the USPTO record | |
| US 10,329,562 | Structurally designed shRNAs In force · From the USPTO record | In force | From the USPTO record | |
| US 12,351,802 | Structurally designed shRNAs In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 56: 8 patents in force now held by others · 62 lapsed for an unpaid fee · 92 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 46 abandoned · 44 no status recorded